Look back at pharma news in the week to May 15, 2020

17 May 2020

By Barbara Obstoj-Cardwell. Editor

Negative research news last week included France’s Genfit adding to the list of failures in non-alcoholic steatohepatitis (NASH) last week with Phase III data on its elafibranor. On a positive note, US firm MyoKardia posted promising results from a Phase III study of its mavacamten for the treatment of hypertrophic cardiomyopathy. Regulatory developments included a setback for US biotech bluebird bio and its partner Bristol-Myers Squibb with the US Food and Drug Administration refusing to review their Biologic License Application for their CAR-T therapy immune-oncology drug lisocabtagene maraleucel. Elsewhere, US biotech Novavax last week announced additional funding of $384 million from the CEPI to advance development of its COVID-19 vaccine candidate NVX-CoV2373.

Genfit’s predictable lover disease failure sets up a cirrhosis pivot

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK